Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus.

Rasoolinejad M, Jafari S, Montazeri M, Mohseni M, Foroughi M, Moradmand Badie B, Saatian M, Marashi SM, Mokhtari Azad T.

Acta Med Iran. 2013 Apr 6;51(3):148-52.

2.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

3.

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.

Vaccine. 2013 May 1;31(19):2358-65. doi: 10.1016/j.vaccine.2013.03.008. Epub 2013 Mar 13.

PMID:
23499604
4.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
5.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
6.

Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.

Hum Vaccin Immunother. 2014;10(2):441-8. doi: 10.4161/hv.27140. Epub 2013 Nov 15.

7.

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.

Ansaldi F, Valle L, de Florentiis D, Parodi V, Murdaca G, Bruzzone B, Durando P, Setti M, Icardi G.

Hum Vaccin Immunother. 2012 Aug;8(8):1048-52. doi: 10.4161/hv.20347. Epub 2012 Aug 1.

8.

Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.

Kelly D, Burt K, Missaghi B, Barrett L, Keynan Y, Fowke K, Grant M.

BMC Immunol. 2012 Aug 31;13:49. doi: 10.1186/1471-2172-13-49.

9.

Short communication: immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents.

Machado AA, Machado CM, Boas LS, Lopes MC, Gouvêa Ade F, Succi RC, Mendoza TR, Kanashiro TM, Machado DM.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):999-1003. doi: 10.1089/AID.2010.0306. Epub 2011 Mar 1.

PMID:
21284525
10.

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.

Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.

Vaccine. 2011 Nov 15;29(49):9209-13. doi: 10.1016/j.vaccine.2011.09.103. Epub 2011 Oct 3.

PMID:
21974995
11.

Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.

Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, Echeverry M, Arango AE, Prada MC, Alarcon Hdel P, Rojas M.

Mem Inst Oswaldo Cruz. 2007 Jun;102(4):501-8.

12.

Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.

Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C, Valette M, Cutland CL, Sanne I.

Clin Infect Dis. 2011 Jan 1;52(1):128-37. doi: 10.1093/cid/ciq004.

13.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.

Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.

Microbiol Immunol. 2015 Oct;59(10):597-604. doi: 10.1111/1348-0421.12316.

PMID:
26272602
14.

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.

Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP.

PLoS One. 2011 Jan 31;6(1):e16496. doi: 10.1371/journal.pone.0016496.

15.

Kinetics of the antibody response to seasonal influenza vaccination among the elderly.

Kositanont U, Assantachai P, Wasi C, Puthavathana P, Praditsuwan R.

Viral Immunol. 2012 Dec;25(6):471-6. doi: 10.1089/vim.2012.0024. Epub 2012 Oct 12.

PMID:
23061793
16.

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.

17.

Antibody responses after dose-sparing intradermal influenza vaccination.

Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P.

Vaccine. 2007 Jan 8;25(4):659-63. Epub 2006 Sep 1.

PMID:
17011678
18.

Vaccination against influenza in patients with systemic sclerosis.

Litinsky I, Balbir A, Zisman D, Mandelboim M, Mendelson E, Feld J, Braun Y, Anouk M, Kaufman I, Paran D, Caspi D, Elkayam O.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S7-11. Epub 2012 May 29.

PMID:
22409886
19.

Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.

Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, Thomas T, Liberty A, Treurnich F, Cutland CL, Weinberg A, Violari A.

AIDS. 2013 Jan 28;27(3):369-79. doi: 10.1097/QAD.0b013e32835ab5b2.

PMID:
23032417
20.

Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects.

Yanagisawa N, Maeda K, Ajisawa A, Imamura A, Suganuma A, Ando M, Takayama N, Okuno Y.

Vaccine. 2011 Aug 5;29(34):5694-8. doi: 10.1016/j.vaccine.2011.06.003. Epub 2011 Jun 29.

PMID:
21689709
Items per page

Supplemental Content

Write to the Help Desk